Clin Mol Hepatol.  2023 Apr;29(2):242-251. 10.3350/cmh.2023.0102.

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective

• Koga H
• Iwamoto H
• Suzuki H
• Shimose S
• Nakano M
• Kawaguchi T

• KMID: 2541403
• DOI: http://doi.org/10.3350/cmh.2023.0102

Abstract

Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.

Keyword

BCLC staging; Radiofrequency ablation; Transcatheter arterial chemoembolization; Molecular-targeted agents; Immune checkpoint inhibitors